3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Multiple Myeloma
188
Lymphoma, Mantle-Cell
34
Neoplasms, Plasma Cell
32
Lymphoma
32
Recurrence
26
Lymphoma, Follicular
20
Waldenstrom Macroglobulinemia
18
Lymphoma, Non-Hodgkin
17
Precursor Cell Lymphoblastic Leukemia-Lymphoma
13
Lymphoma, Large B-Cell, Diffuse
13
Lymphoma, B-Cell, Marginal Zone
13
Carcinoma, Non-Small-Cell Lung
13
Immunoglobulin Light-chain Amyloidosis
10
Neoplasms
9
Leukemia, Myeloid, Acute
9
Lymphoma, B-Cell
8
Renal Insufficiency
7
Leukemia, Lymphocytic, Chronic, B-Cell
7
Leukemia
7
Hodgkin Disease
6
Lymphoma, T-Cell, Peripheral
5
Lymphoma, T-Cell
5
Prostatic Neoplasms
4
Myelodysplastic Syndromes
4
Kidney Neoplasms
4
Carcinoma, Renal Cell
4
Breast Neoplasms
4
Brain Neoplasms
4
Amyloidosis
4
Stomach Neoplasms
3
Interventions
enzalutamide
3
testosterone 17 beta-cypionate
2
darolutamide
2
abiraterone
2
Docetaxel
2
Androgen Antagonists
2
sipuleucel-T
1
pamiparib
1
olaparib
1
lactitol
1
fluciclovine F-18
1
enfortumab vedotin
1
cabazitaxel
1
avelumab
1
Standard of Care
1
Selegiline
1
Prednisolone
1
Pluvicto
1
PSMA-617
1
Gonadotropin-Releasing Hormone
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Metastatic Castration-resistant Prostate Cancer
×
Bortezomib
×
Clear all
NCT06029998
2025-11-28
BORXPTEN
University of Utah
Phase 2
Recruiting
22 enrolled